Ranibizumab (Genentech)

Taylor Tieden for BioSpace Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s Alzheimer’s drug Leqembi, which, according to Eisai, could “help reduce the burden on healthcare professionals and patients.” August is shaping up to be another busy and back-heavy month for the FDA, with at least eight target action dates lined up, including for some drugs that could open up completely new treatment pathways for rare diseases. Read below for more. Insmed Builds Up to First Bronchiectasis Approval New Jersey’s Insmed is proposing its oral DPP1 blocker brensocatib for the treatment of bronchiectasis, a chronic lung disease involving inflamed airways. The FDA is expected to decide on the matter on or before Aug. 12. If approved, brensocatib will be the first drug for bronchiectasis, and will open up the inhibition of DPP1 as a therapeutic mechanism. Insmed’s application is backed by the Phase III ASPEN study. Toplined in May 2024 , ASPEN showed that 10-mg brensocatib cut the annualized pulmonary exacerbation rate by 21.1% versus placebo. A 25 mg dose, meanwhile, led to a 19.4% drop. Brensocatib also hit the study’s secondary outcomes, including lung function, time to first exacerbation event and risk of exacerbations over 52 weeks. Tonix’s Fibromyalgia Drug Nears Verdict By Aug. 15, the FDA will release its decision on Tonix Pharmaceuticals’ non-opioid candidate TNX-102 SL, being proposed for the management of fibromyalgia. If it gets the go-ahead, TNX-102 SL would be the first therapy approved for this indication in more than 15 years, according to a March press release from the company. Designed to be taken orally via a tablet under the tongue, TNX-102 SL is a novel formulation of cyclobenzaprine hydrochloride, a non-opioid drug. Data from two pivotal trials, published in April, showed that the drug candidate can significantly reduce pain and elicit other clinical improvements, while also being tolerable. PTC Pushes Vatiquinone Forward in Friedrich’s Ataxia Despite Phase III Fail Fresh off the approval of its phenylketonuria therapy Sephience, PTC Therapeutics is approaching another decision date, this time for vatiquinone, an investigational drug for Friedreich’s ataxia. The FDA’s verdict is due Aug. 19. Vatiquinone is an investigational small-molecule drug that selectively blocks the 15-lipoxygenase enzyme, which regulates pathways involved in oxidative stress that are dysfunctional in Friedreich’s ataxia. The registration-directed late-stage MOVE-FA trial fell short of its primary endpoint, unable to significantly slow disease progression versus placebo. This study, nonetheless, formed part of PTC’s application for vatiquinone. Two long-term studies in pediatric and adult patients also support vatiquinone’s application. Ionis Targets HAE Prophylaxis Nod for Donidalorsen By Aug. 21, the FDA will release its decision on Ionis Pharmaceuticals’ proposal to use the RNA-targeting therapy donidalorsen to prevent attacks in patients with hereditary angioedema (HAE), a rare genetic disease that manifests as recurring episodes of severe swelling throughout the body. Ionis is backing its application with data from the Phase III OASIS-HAE and OASISplus trials. Data from the first trial, published in May 2024 , showed that monthly treatment with donidalorsen could cut HAE attacks by 81% versus placebo over a 25-week observation period. The second study, meanwhile, demonstrated that switching to donidalorsen from other prophylactics reduced the monthly HAE attack rate by 62%, as per a July readout . Donidalorsen works by reducing levels of the prekallikrein protein, which is involved in the inflammatory cascade. Outlook Eyes AMD Approval for New Avastin Formulation Outlook Therapeutics is advancing ONS-5010, an eye drop formulation of the anti-VEGF antibody bevacizumab—approved as an intravenous infusion under the brand name Avastin for various cancers—for the treatment of wet age-related macular degeneration. The FDA is scheduled to release its decision on Aug. 27. To support its regulatory application, Outlook conducted the Phase III NORSE EIGHT study, which in January showed that ONS-5010 could match Roche’s Lucentis in terms of improving visual acuity at 8 weeks. Retinal thickness, an indicator of anatomic response, was likewise comparable between patients treated with ONS-5010 and Lucentis. The FDA previously rejected ONS-5010, flagging in August 2023 a lack of evidence to support the drug’s efficacy. If approved, Outlook plans to market ONS-5010 under the brand name Lytenava. Precigen Anticipates First Approval in Recurrent Respiratory Papillomatosis Maryland’s Precigen is advancing the gene therapy PRGN-2012, also called zopapogene imadenovec, for the treatment of recurrent respiratory papillomatosis (RRP). The FDA is expected to render a verdict on Aug. 27. RRP is a rare and lifelong neoplastic lung disease affecting the upper and lower respiratory tract after HPV infection. Patients suffer from benign tumors growing in their air passages, causing voice hoarseness, difficulty swallowing and breathing problems. RRP can be fatal, according to Precigen, and there are currently no cures. PRGN-2012 induces the immune system to target cells infected with HPV 6 or HPV 11. Data from a pivotal Phase I/II study showed that the gene therapy can elicit more than a 50% complete response in RRP patients, while more than 85% of patients saw reductions in surgical interventions. If approved, PRGN-2012 will be the first treatment for RRP. Sanofi Targets Rare Disease Approval for Rilzabrutinib The FDA is currently reviewing Sanofi’s application for BTK inhibitor rilzabrutinib for the treatment of immune thrombocytopenia (ITP). A regulatory decision is expected on Aug. 29. ITP is a rare autoimmune disorder that manifests as low platelet counts arising from both heightened destruction and reduced production of platelets. Common symptoms include bruising and bleeding that, in more severe instances, can become life-threatening, such as in the case of intracranial hemorrhage. Rilzabrutinib, an orally available BTK blocker, helps address ITP by tamping down several inflammatory and immune pathways. Phase III data presented at the 2024 meeting of the American Society of Hematology last December showed that 65% of treated patients demonstrated platelet response , defined as a doubling of platelets from baseline and hitting a certain count threshold. This response was durable for at least eight of the last 12 weeks of the study in 23% of patients. Rilzabrutinib likewise resulted in bleeding improvements and lowered the need for rescue therapy versus placebo. Biogen, Eisai’s Subcutaneous Leqembi Could Reduce Treatment Burden The FDA will cap off the month with arguably its most closely watched regulatory action: A verdict , due on Aug. 31, for Biogen and Eisai’s proposed subcutaneous maintenance formulation of their anti-amyloid Alzheimer’s therapy Leqembi. If approved, the partners expect an under-the-skin delivery method could minimize the need for hospital visits and, in turn, “help reduce the burden on healthcare professionals and patients,” according to a February 2025 company presentation from Eisai. The companies are also planning a regulatory filing for a subcutaneous induction formulation of Leqembi next year. Data from the open-label extension phase of the Phase III Clarity AD study supported the subcutaneous application. Results in October 2023 showed that weekly injections under the skin were able to remove 14% more amyloid plaques than biweekly infusions. Subcutaneous Leqembi also appeared to be as safe as the intravenous formulation, with comparable rates of amyloid-related imaging abnormalities.

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its financial results for the first half of 2025. Growth in this document is shown at constant currencies (CC)[1] unless stated otherwise. FINANCIAL RESULTS H1 2025H1 2024changeUSD mUSD mUSD %CC %CGR %[2] Net sales5,2325,0474%4%6% Generics3,7363,7041%1%2% Biosimilars1,4961,34311%12%17% Core EBITDA1,04688518%20% Core EBITDA margin (%)20.0%17.5% Core diluted earnings per share (USD)1.461.1230%33% Management free cash flow503237nm[3] Richard Saynor, Chief Executive Officer of Sandoz, said: “The first half of the year marked another phase of good progress for Sandoz. Strong underlying sales growth was underpinned by the double-digit performance from our biosimilars which, in the second quarter, represented 30% of net sales for the first time, marking a true milestone for the company. Europe and International also performed particularly well, while we launched more important medicines for patients in North America. “Reflecting this year’s launch program, weighted to the second half, we anticipate an even stronger sales performance in the second half, particularly in North America. Further investments in our biosimilars future, in Slovenia and via the proposed acquisition of Just-Evotec Biologics EU SAS, reflect the latest step in our strategic plan to capitalize on the unprecedented patent-expiries’ opportunity over the next ten years. This will only be enhanced by the effects of regulatory streamlining. It is the combination of the growing platform of opportunities, consistently strong financial results and our unrelenting focus on patients that offers such attractive long-term value for our stakeholders.” FINANCIAL HIGHLIGHTS H1 2025 net sales of USD 5,232 million: Up by 4% at CC and USD, with volume growth of 7%; on a CGR basis, H1 net sales grew by 6%In the second quarter, accelerated growth of 5% at CC and 8% in USD; growth of 7% at CGRBiosimilars H1 sales up by 12% at CC and 17% at CGRH1 generics growth of 1% at CC and 2% at CGRThe 10 largest-selling medicines grew by a combined 10% at CC and represented 33% of net sales A core EBITDA margin in H1 of 20.0%, representing a 2.5 percentage-point year-on-year improvement, primarily driven by operating leverage and the mix of salesManagement free cash flow in H1 of USD 503 million (H1 2024: USD 237 million). Free cash flow of USD 207 million (H1 2024: USD 21 million)Core diluted earnings per share of USD 1.46 in H1 represented growth of 33% at CC and 30% in USDFull-year 2025 guidance confirmed: mid-single-digit net-sales growth at CC and a core EBITDA margin of around 21% BUSINESS HIGHLIGHTS There were a number of business highlights since the publication of the Q1 2025 sales update. Biosimilars The company recently signed a non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics’ in-house development and manufacturing capabilities in Toulouse, France. The proposed transaction would seamlessly align with the strategic objective of capitalizing on the projected USD 300 billion biosimilar-market opportunity over the next 10 years[4]Sandoz recently announced the start of construction for a new, state-of-the-art biosimilars production center for sterile product manufacturing in Brnik, Slovenia. This complements ongoing investments in Slovenia, namely a new biosimilar drug-substance production center in Lendava and a biosimilar development center in LjubljanaFollowing feedback from major regulatory authorities, Sandoz has decided to streamline the clinical-development programs for its proposed nivolumab and ocrelizumab biosimilars, respectively. The company is winding down the Phase III NivoReach trial for its proposed biosimilar nivolumab. Sandoz is also modifying its Strive-MS integrated Phase I/III trial to become a comparative pharmacokinetic trial for its proposed ocrelizumab biosimilar. The development programs, including comprehensive analytical and clinical pharmacokinetic data, have been designed to align with updated regulatory guidance and confirm biosimilarity to their respective reference medicines, while maintaining the highest scientific and regulatory standardsThe aforementioned streamlining reflects ongoing encouraging and favorable regulatory developments for biosimilars and follows Sandoz’s decision earlier in the year to minimize its Phase III trial for its proposed pembrolizumab biosimilar Launches Sandoz recently launched Wyost® and Jubbonti® in the US, the first and only interchangeable denosumab biosimilars. Pyzchiva® (ustekinumab) was also launched in the US, including in private label. Finally, a Pyzchiva autoinjector was also rolled out to become the first commercially available ustekinumab biosimilar in a pre-filled pen in EuropeAnticipated biosimilar launches in the second half of the year include Wyost & Jubbonti and Afqlir® (aflibercept) in Europe, while the company retains its ambition to launch Tyruko® (natalizumab) in the US before the end of the year[5] FULL-YEAR 2025 GUIDANCE The company expects further major biosimilar launches this year, while price erosion is expected to return to normalized levels of a low to mid-single-digit percentage. Sandoz continues to anticipate core EBITDA-margin expansion this year to reflect the mix of sales, simplification of the external network and the ongoing transformation program. As a result, the company confirms its expectations for 2025: Net sales to grow at CC by a mid-single-digit percentageA core EBITDA margin in FY 2025 of around 21% This guidance excludes any impacts of unforeseen events or unconfirmed developments, such as significant further potential trade tariffs emanating from the US government. H1 AND Q2 2025 NET SALES Net sales by business H1 H1 2025% of net salesH1 2024changeUSD m USD mUSD %CC %CGR % Generics3,736713,7041%1%2%Biosimilars1,496291,34311%12%17%Net sales5,2321005,0474%4%6% Net sales for the first half of 2025 were USD 5,232 million, up by 4% at CC and by 6% at CGR. Volumes grew by 7%, partly offset by price erosion of 3%; the erosion was in line with a full-year assumption of a low to mid-single-digit decline. Net-sales growth was primarily driven by the performance of biosimilars, which continues to benefit from an extensive pipeline and launch program. Generics overviewNet sales of generics in H1 were USD 3,736 million, reflecting growth of 1% at CC and 2% at CGR. Generics represented 71% of net sales (H1 2024: 73%, Q2 2025: 70%). Europe net sales of generics grew by 2% at CC in the first half, reflecting the impact of launches in 2024. International net sales of generics declined by 1% at CC; after adjusting for the 2024 divestment of the Sandoz business in China, International net sales of generics grew by 3% at CGR. In North America, generics net-sales growth of 2% at CC benefited from the successful launch of paclitaxel in 2024. Biosimilars overviewNet sales of biosimilars in H1 of USD 1,496 million reflected growth of 12% at CC and 17% at CGR. Biosimilars represented 29% of total net sales (H1 2024: 27%, Q2 2025: 30%). Strong Europe biosimilars net-sales growth of 17% at CC benefited from a number of good performances, including recently launched Pyzchiva and Tyruko, while strong International biosimilar net-sales growth of 30% at CC partly reflected the strong contribution from Omnitrope® (somatropin). Major biosimilar launches in International in 2025 will all occur in the second half of the year. North America biosimilar net sales declined by 9% at CC in the half, reflecting the withdrawal of Cimerli in Q1 2025 and the effect of private-label adalimumab pricing; excluding the impact of the 2024 acquisition of Cimerli, North America biosimilar net sales grew by 9%. Q2 Q2 2025% of net salesQ2 2024changeUSD m USD mUSD %CC %CGR % Generics1,927701,8355%2%3%Biosimilars8253072015%12%20%Net sales2,7521002,5558%5%7% Net sales for the second quarter were USD 2,752 million, up by 5% at CC and by 7% at CGR. Volumes grew by 8%, partly offset by price erosion of 3%. Net sales by region H1 H1 2025% of net salesH1 2024changeUSD m USD mUSD %CC %CGR % Europe2,832542,6348%6%6%International1,284251,2691%5%8%North America1,116211,144-2%-1%4%Net sales5,2321005,0474%4%6% Europe overviewNet sales in Europe in H1 were USD 2,832 million, reflecting growth of 6% at CC and CGR. Europe net sales of generics grew by 2% at CC in the first half, with growth in biosimilars of 17% at CC primarily a result of commercial execution and recent launches, including Pyzchiva and Tyruko. International overviewNet sales in International in H1 were USD 1,284 million, with growth of 5% at CC and 8% at CGR. In the second quarter, International net sales grew by 11% at CC and by 13% at CGR, despite major biosimilar launches this year all coming in H2. Pricing increased in generics during the first half of 2025, with strong International biosimilar net-sales growth of 30% at CC partly a result of the continued good performance from Omnitrope. North America overviewNet sales in North America in H1 were USD 1,116 million, reflecting a decline of 1% at CC. Growth at CGR however, namely excluding the impact of the acquisition of Cimerli, amounted to 4%. A good performance from generics was driven by the successful recent launch of paclitaxel, as well as continued strong growth in Canada. Biosimilar net-sales growth would have been positive when excluding the aforementioned impact of the Cimerli acquisition. Price erosion was driven by reduced Cimerli sales, private-label adalimumab pricing and Omnitrope. Q2 Q2 2025% of net salesQ2 2024changeUSD m USD mUSD %CC %CGR % Europe1,460531,30812%6%6%International6942562711%11%13%North America59822620-4%-3%5%Net sales2,7521002,5558%5%7% H1 2025 KEY OPERATING AND NON-OPERATING RESULTS H1 2025H1 2024changeUSD mUSD mUSD %CC % Net sales5,2325,0474%4%Gross profit2,4112,3801%2%Operating income60233281%90%EBITDA87057651%55%Net income377151nmnm Core results Core gross profit2,5752,5441%2%Core gross profit margin (%)49.2%50.4% Core operating income90176318%20%Core operating income margin (%)17.2%15.1% Core EBITDA1,04688518%20%Core EBITDA margin (%)20.0%17.5% Core net income63548431%34%Core diluted earnings per share (USD)1.461.1230%33% Core gross profit amounted to USD 2,575 million (H1 2024: USD 2,544 million), resulting in a core gross profit margin of 49.2% (H1 2024: 50.4%). The favorable product mix from double-digit biosimilars growth, as well as operational improvements, was more than offset by price erosion and inflation on cost of goods sold. Core EBITDA was USD 1,046 million (H1 2024: USD 885 million), resulting in a core EBITDA margin of 20.0% (H1 2024: 17.5%). The strong increase was primarily driven by leveraging expenses from a growing top line and savings from the transformation program. EBITDA was USD 870 million (H1 2024: USD 576 million). Core adjustments for EBITDA in the first half of 2025 were USD 176 million (H1 2024: USD 309 million). These were mainly driven by separation costs of USD 156 million, costs of rationalization of internal manufacturing sites of USD 54 million and favorable impacts from adjustments for legal costs of USD 28 million. Core net income was USD 635 million (H1 2024: USD 484 million), mainly driven by higher core operating income and a lower core net financial result, partly offset by higher core income taxes, while the effective tax rate remained broadly unchanged. Core diluted earnings per share were USD 1.46 (H1 2024: USD 1.12). The weighted average number of shares diluted was 435.8 million as of June 30, 2025, versus 432.2 million in the prior-year period. NET CASH FLOW, NET WORKING CAPITAL AND NET DEBT H1 2025H1 2024changeUSD mUSD mUSD m Net cash flows from operating activities523229294Cash flows used for net capex(310)(205)(105)Free cash flow20721186Management free cash flow503237266 Sandoz generated net cash flows from operating activities of USD 523 million in the first half of the year (H1 2024: USD 229 million). This was mainly driven by working-capital enhancements through improvements in receivables; inventory levels were stable versus December 2024. Cash flows used for capital expenditures were USD 310 million (H1 2024: USD 205 million). This included the company’s ongoing investment in Slovenia, namely a new biosimilar drug substance production center in Lendava, a biosimilar development center in Ljubljana and a new production plant in Brnik. It also included separation-related investments in facilities and technology. Management free cash flow, defined as free cash flow adjusted for one-off items, was USD 503 million (H1 2024: USD 237 million). The increase was mainly driven by a higher core EBITDA. Free cash flow amounted to USD 207 million (H1 2024: USD 21 million). The improvement was mainly due to increased net cash flows from operating activities, partly offset by higher cash flows used for capital expenditures. Jun 30, 2025Dec 31, 2024changeUSD mUSD mUSD m Net working capital3,6383,486152Net debt3,9093,329580 Net working capital increased by USD 152 million, largely due to currency-translation effects of USD 305 million, offset by improvements in underlying net working capital. Non-current financial debt increased by USD 811 million, reflecting the issuance of three bonds in the first half of 2025 of EUR 500 million and CHF 400 million, respectively and currency-translation effects. This was partly offset by the repayment of USD 750 million equivalent in USD and EUR term loans. Cash and cash equivalents increased by USD 198 million as cash generated from operating activities and proceeds from the issuance of non-current financial debt were partly offset by the repayment of term loans, the annual dividend payment and purchases of property, plant and equipment. As a result of the above, net debt increased to USD 3.9 billion compared to USD 3.3 billion on December 31, 2024, mainly related to currency-translation effects of USD 422 million. CONFERENCE CALL A conference call and webcast for investors and analysts will begin today at 9am CET. Details can be found here, with the accompanying presentation here. NOTES The performance shown in this announcement covers the six-month period to June 30, 2025 (H1 2025) and the three-month period to June 30, 2025 (Q2 2025), compared to the six-month period to June 30, 2024 (H1 2024) and the three-month period to June 30, 2024 (Q2 2024), respectively. Commentary is based on the performance in H1 2025, unless stated otherwise. CALENDAR The company intends to publish its nine-months’ and third-quarter sales update on October 30, 2025. HALF-YEAR REPORT Sandoz published its Half-Year Report 2025 today, which can be found here. [1] Non-IFRS measures are defined in the Supplementary financial information section of the Half-Year Report 2025. [2] Sandoz defines the comparable growth rate (CGR) as the growth rate of net sales at CC excluding the effects of material acquisitions and divestments. In the case of divestments, net sales are excluded for the corresponding period. Similarly, for acquisitions, the relevant net sales are excluded for the corresponding period. Material acquisitions and divestments are transactions in scope of significant transactions in the company’s Consolidated financial statements. Sandoz believes the presentation of CGR is meaningful for management and investors to evaluate the performance of the business over time. In this announcement, adjustments relate to the impact of the 2024 acquisition of US biosimilar Cimerli® (ranibizumab) and the 2024 divestment of the Sandoz business in China. [3] Not meaningful. [4] Based on March 2025 data from IPD Analytics Evaluate Pharma, covering the period 2026–2035.[5] Subject to regulatory approval of John Cunningham virus assay and pending litigation. CONTACTS Media RelationsInvestor Relationsglobal.mediarelations@sandoz.cominvestor.relations@sandoz.comAlex Kalomparis+41 79 279 02 85Craig Marks+44 7818 942 383Joerg E. Allgaeuer+49 171 838 4838Tamara Hackl+41 79 790 52 17Danja Spring+41 79 156 74 88Rupreet Sandhu+41 79 410 54 72 DISCLAIMER This media release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. This media release includes non-IFRS financial measures as defined by Sandoz. An explanation of non-IFRS measures can be found in the Supplementary financial information section of the Half-Year Report 2025. ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. SUPPORTING FINANCIAL INFORMATION 2025 NET SALES By business Q1 2025change Q2 2025change H1 2025change USD mUSD %CC % USD mUSD %CC % USD mUSD %CC %Generics 1,809-3%0% 1,9275%2% 3,7361%1%Biosimilars6718%11% 82515%12% 1,49611%12%Net sales 2,4800%3% 2,7528%5% 5,2324%4% By region Q1 2025change Q2 2025change H1 2025change USD mUSD % CC % USD mUSD %CC % USD mUSD %CC %Europe 1,3723%7% 1,46012%6% 2,8328%6%International590-8%-2% 69411%11% 1,2841%5%North America518-1%1% 598-4%-3% 1,116-2%-1%Net sales 2,4800%3% 2,7528%5% 5,2324%4% By region and business H1 2025H1 2024changeUSD mUSD mUSD %CC %CGR % Europe2,8322,6348%6%6%Generics1,9411,8813%2%2%Biosimilars89175318%17%17%International1,2841,2691%5%8%Generics1,0191,055-3%-1%3%Biosimilars26521424%30%30%North America1,1161,144-2%-1%4%Generics7767681%2%2%Biosimilars340376-10%-9%9%Net sales5,2325,0474%4%6% 2024 NET SALES By business Q1 2024change Q2 2024change Q3 2024change Q4 2024change USD mUSD %CC % USD mUSD %CC % USD mUSD %CC % USD mUSD %CC %Generics 1,86901 1,835-11 1,85434 1,94614Biosimilars6232121 7203537 7413637 7692325Net sales 2,49256 2,55579 2,5951112 2,71579 By region Q1 2024change Q2 2024change Q3 2024change Q4 2024change USD mUSD %CC % USD mUSD %CC % USD mUSD %CC % USD mUSD %CC %Europe 1,32642 1,30823 1,3621312 1,36778International642412 62759 63528 65306North America52466 6202223 5981718 6951314Net sales 2,49256 2,55579 2,5951112 2,71579 H1 2025: RECONCILIATION FROM IFRS RESULTS TO CORE RESULTS (USD millions unless indicated otherwise)IFRS resultsAmorti-zation of intangibleassets[6]Impair-ments[7]Acquisition or divest-ment of businesses and related items[8]Other items[9]Core resultsNet sales5,232––––5,232Other revenues33––––33Cost of goods sold(2,854)10115–48(2,690)Gross profit2,41110115–482,575Selling, general and administration(1,192)–––10(1,182)Development and regulatory(504)–1–2(501)Other income222––(10)(109)103Other expense(335)–––241(94)Operating income[10]60210116(10)192901Interest expense(111)––––(111)Other financial income and expense13–––316Income before taxes50410116(10)195806Income taxes[11](127) (171)Net income 377 635Basic earnings per share (USD)0.87 1.47Diluted earnings per share (USD)0.87 1.46 [6] Amortization of intangible assets: cost of goods sold includes the amortization of rights to currently marketed products and other production-related intangible assets.[7] Impairments: cost of goods sold and development and regulatory include impairment charges related to intangible assets. [8] Acquisition or divestment of businesses and related items: other income includes a release related to the China business divestment.[9] Other items: cost of goods sold, other income and other expense include the Group-wide rationalization of manufacturing sites; cost of goods sold, selling general and administration, development and regulatory, other income and other expense include the separation costs related to the spin-off; selling general and administration, development and regulatory, other income and other expense include the costs related to the transformation program and other restructuring charges; other income and other expense include legal related charges and adjustments to contingent considerations; other expense includes an onerous contract adjustment; other financial income and expense includes the net monetary impacts on the restatement of non-monetary items for subsidiaries in hyperinflationary economies.[10] For further breakdown of core adjustments by category, refer to table Reconciliation from IFRS operating income to core net income in the Half-Year Report 2025.[11] Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Due to these factors and the differing applicable tax rates in the various jurisdictions, the tax on the total adjustments of USD 302 million to arrive at the core results before tax amounts to USD 44 million. The average tax rate on the adjustments was 14.6%. Further reconciliations of core results are available in the Supplementary financial information of the Half-Year Report 2025, which can be found here. Attachment Media release_H1 2025